The Conundrum of Toxic Epidermal Necrolysis

Gérald E. Piérard, MD, PhD
Dept of Dermatopathology, University Hospital of Liège, Belgium

Philippe Paquet, MD, PhD
University of Liege, Department of Dematophathology, University Hospital, Liege, Belgium

Serge Jennes, MD
Physician Colonel, Head of the Burn Wound Center of the Military Hospital Queen Astrid, Brussels

Claudine Franchimont, MD, PhD
University of Liege, Department of Dematophathology, University Hospital, Liege, Belgium

Series: Emergency and Intensive Care Medicine
BISAC: MED017000

Clear

$192.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Adverse drug reactions commonly affect the skin. In rare instances, they cause severe morbidity and possibly lead to drug-induced mortality. Toxic epidermal necrolysis (TEN) represents the archetype of such conditions.

This book summarizes the recent advances in the field of TEN as a major life-threatening adverse drug reaction. Indeed, this dramatic condition remains a puzzling topic for both the clinician at the bedside and in the laboratory. This book is fully updated about the putative biomechanisms, the clinico-pathological correlations and recent treatment advances.

The most damaging effects of TEN reside in the skin, eyes and oral mucosa. Physicians keen in intensive care medicine, dermatology and ophthalmology should find here stimulating concepts applicable to the patient with the hope of reducing the TEN fatalities. (Imprint: Nova Biomedical)

Preface

Introduction

Acronyms and Abbreviations

Part I: General Considerations

Chapter 1 - From Lyell’s Syndrome to Toxic Epidermal Necrolysis (pp. 3-4)

Chapter 2 - The Keratinocyte, Major Target and Actor (pp. 5-10)

Chapter 3 - Immunological Mechanisms (pp. 11-12)

Part II: Clinico-Pathologic Features

Chapter 4 - Cutaneous and Mucosal Clinical Presentations (pp. 15-18)

Chapter 5 - Extracutaneous Involvement (pp. 19-28)

Chapter 6 - Histopathology (pp. 29-32)

Chapter 7 - Proteomic Kinetic Analysis (pp. 33-34)

Chapter 8 - Differential Diagnosis (pp. 35-44)

Chapter 9 - Drug Impact (pp. 45-46)

Chapter 10 - Pharmacogenetics (pp. 47-48)

Chapter 11 - Lymphocytic Impact (pp. 49-52)

Chapter 12 - Monocyte-Macrophage and Mesenchymal Cell Impact (pp. 53-54)

Chapter 13 - Keratinocyte Pathobiology and Demise (pp. 55-70)

Chapter 14 - Analytic Skin Biometrology (pp. 71-74)

Part III: Management

Chapter 15 - TEN Prevention (pp. 77-78)

Chapter 16 - Prognosticators (pp. 79-84)

Chapter 17 - Supportive Care Management (pp. 85-88)

Chapter 18 - Survival Management (pp. 89-90)

Chapter 19 - Topical Treatment (pp. 91-98)

Chapter 20 - Systemic Pharmacotherapy (pp. 99-106)

Chapter 21 - Tissue Replacement (pp. 107-108)

Chapter 22 - Cost-Effectiveness of Treatment (pp. 109-110)

Part IV: Framing the Future

Chapter 23 - Spotlight on Perspective (pp. 113-116)

References

Index

Audience: Medical students, dermatologists, intensive care physicians, burn units, ophthalmologists.

You have not viewed any product yet.